<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395434</url>
  </required_header>
  <id_info>
    <org_study_id>OXC4P1-105</org_study_id>
    <nct_id>NCT00395434</nct_id>
  </id_info>
  <brief_title>Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mateon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mateon Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of three dose levels of&#xD;
      combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab&#xD;
      every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be&#xD;
      defined if it is at one of the three dose levels under study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of the combination therapy assessed by analysis of adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>safety and tolerability of the combination therapy assessed by analysis of laboratory tests</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>safety and tolerability of the combination therapy assessed by analysis of other assessments within the protocol</measure>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combretastatin A4 Phosphate (CA4P)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (Avastin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histopathologically or cytologically confirmed malignant solid tumors that have failed&#xD;
             standard therapy or for which no life prolonging treatment exists&#xD;
&#xD;
          2. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) criteria&#xD;
&#xD;
          3. At least 4 weeks since any prior immunotherapy, chemotherapy or radiation therapy&#xD;
             prior to first dose of study drug (six weeks for therapy known to be associated with&#xD;
             delayed toxicity such as nitrosoureas or mitomycin-C)&#xD;
&#xD;
          4. Age &gt; or = to 18 years old&#xD;
&#xD;
          5. Adequate bone marrow function:&#xD;
&#xD;
               1. absolute granulocyte count (neutrophils and bands) &gt; or = to 1500 cells/mm3;&#xD;
&#xD;
               2. platelet count &gt; or = to 100,000 cells/mm3;&#xD;
&#xD;
               3. hemoglobin &gt; or = to 9 g/dL.&#xD;
&#xD;
          6. Adequate renal function (glomerular filtration calculated by Cockcroft/Gault formula&#xD;
             or measure urine creatinine clearance &gt; or = to 50 mL/minute)&#xD;
&#xD;
          7. Adequate hepatic function:&#xD;
&#xD;
               1. bilirubin less than or = to 1.5 mg/dL;&#xD;
&#xD;
               2. aspartate transaminase (AST) and alanine transaminase (ALT) less than or = to 2.5&#xD;
                  times the institutional upper limit of normal (ULN) (or less than or = to 5 times&#xD;
                  ULN if liver metastases are present).&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          9. Life expectancy of &gt; or = to 12 weeks&#xD;
&#xD;
         10. Written, signed, dated, and witnessed (if applicable as per International Conference&#xD;
             on Harmonization [ICH] guidelines) Independent Ethics Committee (IEC) approved&#xD;
             informed consent form before any study specific screening procedures are performed&#xD;
&#xD;
         11. Fertile subjects must abstain from sexual intercourse or use effective birth control.&#xD;
&#xD;
         12. All women of child bearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 72 hours of first dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications, allergies or sensitivity to the use of the study medications or any&#xD;
             other products required for participation in this study (i.e. contrast agents)&#xD;
&#xD;
          2. Presence of central nervous system (CNS) metastases&#xD;
&#xD;
          3. Diagnosed squamous non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          4. History of gastrointestinal perforations&#xD;
&#xD;
          5. Surgery within 28 days of screening visit or a surgical incision that is not fully&#xD;
             healed. Any surgery planned during the study period.&#xD;
&#xD;
          6. Proteinuria &gt;1 g/24 hours by 24 hour urine collection (perform 24 hour urine&#xD;
             collection if &gt; 1+ on dipstick)&#xD;
&#xD;
          7. Recent hemoptysis (occurrence within the past 3 months)&#xD;
&#xD;
          8. Prior therapy with CA4P or bevacizumab, or other agents which target vascular&#xD;
             endothelial growth factor (VEGF) or VEGFR signaling such as Sorafenib and Sutent&#xD;
&#xD;
          9. Prior radiation involving &gt; 30% of the bone marrow&#xD;
&#xD;
         10. Radical radiotherapy to the thorax or abdomen at any time or post-operative radical&#xD;
             radiotherapy to the pelvis. Palliative radiotherapy treatments are acceptable.&#xD;
             Subjects with rectal primaries who have received pre-operative pelvic radiotherapy or&#xD;
             chemoradiation are eligible if the small bowel was mobile and not stuck to the tumor.&#xD;
&#xD;
         11. Active autoimmune disorder(s)&#xD;
&#xD;
         12. Immunocompromised, including subjects known to be human immunodeficiency virus (HIV)&#xD;
             positive&#xD;
&#xD;
         13. Active infection requiring antibiotic therapy or any other serious intercurrent&#xD;
             illness&#xD;
&#xD;
         14. History of angina (stable or severe, even if controlled with medications), myocardial&#xD;
             infarction, congestive heart failure (CHF), non-controlled atrial arrhythmias or&#xD;
             clinically significant arrhythmias including conduction abnormality, nodal junctional&#xD;
             arrhythmias and dysrhythmias, sinus bradycardia or tachycardia, supraventricular&#xD;
             arrhythmias, atrial fibrillation or flutter, syncope or vasovagal episodes&#xD;
&#xD;
         15. Electrocardiogram (ECG) with evidence of prior myocardial infarction (e.g.,&#xD;
             significant Q waves), QTc &gt; 450 msec or other clinically significant abnormalities&#xD;
&#xD;
         16. Taking any drug(s) known to prolong the QTc interval, which cannot be interrupted for&#xD;
             at least four days during each treatment cycle.&#xD;
&#xD;
         17. Known significant heart wall abnormality or heart muscle damage as evidenced on&#xD;
             multiple-gated acquisition (MUGA) scan or echocardiogram (this is not a required&#xD;
             screening investigation)&#xD;
&#xD;
         18. Uncontrolled hypertension (defined as blood pressure consistently greater than 150/100&#xD;
             irrespective of medication). Or controlled hypertension requiring use of &gt; 2 classes&#xD;
             of anti-hypertensives.&#xD;
&#xD;
         19. Uncontrolled hypokalemia and/or hypomagnesemia&#xD;
&#xD;
         20. Symptomatic peripheral vascular disease or cerebrovascular disease&#xD;
&#xD;
         21. Psychiatric disorders or other conditions rendering subjects incapable of complying&#xD;
             with the requirements of the protocol&#xD;
&#xD;
         22. Receiving concurrent hormonal therapy with the exception of gonadotropin-releasing&#xD;
             hormone (GnRH) agonists in subjects with hormone refractory prostate cancer, hormone&#xD;
             replacement therapy (HRT), oral contraceptives, and megestrol acetate used for&#xD;
             anorexia/cachexia&#xD;
&#xD;
         23. Receiving anticoagulation with warfarin, heparin or low molecular weight heparin other&#xD;
             than low dose (1 mg) warfarin for maintenance of central line patency&#xD;
&#xD;
         24. Women who are currently pregnant, nursing, or planning a pregnancy; or women who have&#xD;
             a positive pregnancy test.&#xD;
&#xD;
         25. Receiving concurrent antineoplastic therapy (radiation therapy, cytotoxic or biologic&#xD;
             therapy)&#xD;
&#xD;
         26. Participation in an investigational drug or device trial within 30 days of entering&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Nathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Vernon Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hillori Connors, MS</last_name>
    <role>Study Director</role>
    <affiliation>Mateon Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Harris, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mateon Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <last_update_submitted>October 28, 2011</last_update_submitted>
  <last_update_submitted_qc>October 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Advanced Solid Tumours</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Advanced Solid Tumour</keyword>
  <keyword>Advanced</keyword>
  <keyword>Malignant</keyword>
  <keyword>Solid</keyword>
  <keyword>Tumors</keyword>
  <keyword>Tumours</keyword>
  <keyword>Tumor</keyword>
  <keyword>Tumour</keyword>
  <keyword>Cancer</keyword>
  <keyword>Malignant Solid Tumors</keyword>
  <keyword>Malignant Solid Tumours</keyword>
  <keyword>Malignant Solid Tumor</keyword>
  <keyword>Malignant Solid Tumour</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Metastatic Disease</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Vascular Disrupting Agent</keyword>
  <keyword>Anti-angiogenesis agent</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Combretastatin</mesh_term>
    <mesh_term>Fosbretabulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

